News & Events

July 2, 2013

Fish Leverages Ex Parte Reexamination to Win Federal Circuit case for Fresenius

July 2, 2013
Press Release

Boston, MA, July 2, 2013 — Fish & Richardson announced today that it won an appellate decision in a patent infringement case for Fresenius USA, Inc. and Fresenius Medical Care Holdings, Inc. against Baxter International and Baxter Healthcare Corporation regarding a patent for a hemodialysis machine.  The U.S. Court of Appeals for the Federal Circuit, in a July 2, 2013 decision, held that federal trial and appellate courts are required by statute to dismiss pending patent cases if the U.S. Patent and Trademark Office (PTO) has cancelled the asserted claims through reexamination.

Fresenius sued Baxter in 2003, seeking a declaratory judgment that it did not infringe any valid claims of certain Baxter patents.  Baxter counter-sued for patent infringement.  In 2005 Fresenius hired Fish as new counsel for the district court litigation, and Fish quickly filed a request for ex parte reexamination of Baxter’s patents.

In the district court proceedings, a single Baxter patent survived trial and a 2009 appeal sent the case back to district court for further proceedings on damages issues.  In the meantime, the PTO invalidated the asserted claims in the remaining patent.

Fresenius appealed from the district court and Baxter appealed from the PTO reexamination.  The Federal Circuit heard the reexamination appeal first, affirming the PTO’s ruling that invalidated all the asserted patent claims.  Fresenius then argued in the other appeal that Baxter’s case had to be dismissed because its claims had been cancelled.

In the July 2 ruling, the Federal Circuit agreed, vacated the district court judgment, and remanded with instructions to dismiss the case.  The court recognized and gave effect to its prior affirmance of the PTO’s cancellation of the asserted claims in the appeal from the Patent Office reexamination, even though the court, in the first appeal from the district court, had held that there was not clear and convincing evidence of invalidity before the jury. It reasoned that once the PTO cancelation of the asserted claims was affirmed, the patent owner no longer had a viable cause of action.

Fish’s patent, trial and appellate practices enabled an integrated team of attorneys to seamlessly handle the case from trial through appeal and to initiate the parallel PTO proceedings.  The Fish trial team representing Fresenius included Juanita Brooks, Michael Florey and Thomas Melsheimer; the Fish appellate team included Juanita Brooks, Michael Florey and John Dragseth.  John Phillips filed the request for reexamination.

No Comments

Sorry, the comment form is closed at this time.

Fill out the form below to receive our monthly newsletter and updates on your selected areas of interest. You can unsubscribe at any time by clicking the unsubscribe link at the bottom of the email.

  • Fish & Richardson P.C. is committed to protecting and respecting your privacy, and we’ll only use your personal information to administer your account and to provide the services you requested from us. From time to time, we would like to contact you about our services, as well as other content that may be of interest to you. If you consent to us contacting you for this purpose, please tick below.
  • In order to provide you the content requested, we need to store and process your personal data. If you consent to us storing your personal data for this purpose, please tick the checkbox below.
  • You can unsubscribe from these communications at any time. This can be done by clicking the unsubscribe link at the bottom of marketing emails you receive from us, or by emailing info@fr.com stating that you would like to be unsubscribed.
  • This field is for validation purposes and should be left unchanged.